US 10,744,155 B2 · Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure

Abstract

The present invention provides an inhibitor of an ADAMTS proteoglycanase for use in treating or preventing cardiac remodeling or for use in treating or preventing heart failure in a subject. In particular, the present invention provides an inhibitor of ADAMTS4 or ADAMTS5 for use in treating or preventing cardiac remodeling or chronic heart failure in a subject with cardiac remodeling or with chronic heart failure, or with a condition that may lead to cardiac remodeling and/or chronic heart failure. Also provided is a method of treating or preventing cardiac remodeling or treating or preventing heart failure which method comprises administering to a subject in need thereof a therapeutically effective amount of an inhibitor of an ADAMTS proteoglycanase. Also provided is the use of an inhibitor of an ADAMTS proteoglycanase in the manufacture of a medicament for treating or preventing cardiac remodeling or treating or preventing heart failure.

Claims14

Dependent claims

A method for treating left ventricular remodeling or chronic heart failure in a subject comprising administering a therapeutically effective amount of an inhibitor of ADAMTS4 or ADAMTS5 to a subject having left ventricular remodeling or chronic heart failure,

wherein said subject is further characterized by having, or being suspected of having, a condition selected from the group consisting of cardiomyopathies, heart valve disease, heart valve dysfunction, hypertension, pulmonary hypertension, congenital heart disease, arrhythmias, and coronary artery disease, or wherein said subject has undergone myocardial infarction,
and wherein said inhibitor of ADAMTS4 or ADAMTS5 is not marimastat.

Dependencies are inferred from the claim text.

Facts

Application

16/403,882Filed 6 May 2019 · continuation

Priority

GB 1312311.29 Jul 2013

Published

US 2019/0282606 A119 Sep 2019

Granted

18 Aug 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/737
Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers,…:…
A61K 31/4523
Non condensed piperidines, e.g. piperocaine: containing further heterocyclic ring systems
A61K 31/453
Containing further heterocyclic ring systems: containing a six-membered ring with oxygen as a ring hetero atom
A61P 9/00
Drugs for disorders of the cardiovascular system

Family

PCT/EP2014/064761Parent of this continuation · filed 9 Jul 2014

US 2019/0282606 A1Pre-grant publication · published 19 Sep 2019

Application14/903,624Parent of this continuation

US 10,322,143 B2Parent of this continuation

US 2016/0158271 A1Published application

US 10,744,155 B2This patent

From the US filing history. Foreign family members aren’t listed.

Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure

Life of this patent

Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure

Life of this patent

Abstract

Claims14